Trial Profile
A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Tipapkinogene sovacivec (Primary)
- Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Liver metastases; Oropharyngeal cancer; Penile cancer; Squamous cell cancer; Vulvovaginal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Transgene
- 02 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 02 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.